



PRINCE MAHIDOL AWARD CONFERENCE 2016 | PRIORITY SETTING FOR UNIVERSAL HEALTH COVERAGE

Conference synthesis: Summary & Recommendations

Sunday 31 January 2016
10.00-11.00



Conference programme structure

- Pre-conference: 26 – 28 January 2016
 - 52 side meetings
 - 6 field trips
- Main conference 29 - 31 January 2016
 - 4 Keynote addresses
 - 5 plenary sessions
 - 15 parallel sessions
 - 8 Launches: books, website, program
- Total registered participants,
 - 63 countries; 847 participants (F 39%, M 44%, NA 16%)




Profile: moderators/speakers/panelists


20 Plenary & parallel sessions

Chairs/moderators	26
Speakers	59
Panelists	50
Total	135


Gender



WHO Regions



Organization



Rapporteur

- Each session had three or four rapporteurs
- Pre-meeting for rapporteurs
- Templates for abstract and summary
- Abstracts are used for this session
- Both abstracts and summaries will be used for the conference proceedings
- All presentations are uploaded on the web site :
www.pmaconference.mahidol.ac.th
- Gratefully acknowledge the contributions of all 71 rapporteurs



Global context


- Commitments to Universal Health Coverage (UHC)
 - UNGA Resolution A/70/L.1 “Transforming our world: the 2030 Agenda for Sustainable Development” Oct 2015
 - UHC in SDG3.8
- Commitments to Health Intervention and Technology Assessment (HITA)
 - WHO AMR/PAHO resolution, CSP28.R9 “Health Technology Assessment and Incorporation into Health Systems” Sep 2012
 - WHO SEA Regional Committee Resolution SEA/RC66/R4 “HITA in support of UHC” Sep 2013
 - World Health Assembly Resolution WHA67.23 “HITA in support of UHC”, May 2014
 - *Inter alia*, call for strengthening national capacity, regional and international networking



Matching resources and demand for health

- Health resource is finite, **demand is infinite** in light of demographic, epidemiological transitions, technology advancement and increased expectations
- Government must be accountable to people to make best use of limited public resources
- HITA essential to inform resource allocation
- Goal of PMAC2016
 - Learning and sharing to drive ***Priority Setting for UHC***

Conceptual framework for the conference




Key areas

1. Evidence
2. Using evidence in making UHC decision
3. Priority setting in action



1. Evidence for priority setting

Basic information on priority setting and its technical terms, with in-depth dialogues on current challenges



Markov Meta-analysis HTA
QALY DALY
Economic Evaluation
EQ-5D CEA Utility
CBA ICER
CUA Discount
Decision Tree rate

Evidence - overview

- Priority setting takes place at many different levels
 - Global, national, sectoral, local, individual
- Ministries of Finance consider a range of factors when choosing how much to allocate to health – impact on productivity/growth, cost-effectiveness, evidence that resources are used efficiently; comparisons across sectors are hampered by the absence of appropriate metrics
- Countries increasingly seeking to use evidence of cost-effectiveness in establishing benefit packages
- Lack of country level data on costs and effectiveness leads to reliance on global sources (eg. CHOICE, DCP)
- Range of initiatives to strengthen collection of national cost data –tools need to bridge theory and practical guidance



Evidence: Extending perspectives

- Methods need to take account of health system constraints, and to connect priority setting with the health system architecture
 - Human resources / capital; Costs of implementing changes (transition costs); System interdependencies (eg. economies of scope); Governance and decision making processes
- Such adaptation would aid process of generalisability of evidence across settings, and improve the effectiveness of priority setting
- Scope for wider application of methods which explicitly incorporate multiple criteria in decision making; but given uncertainties, their value may lie in the deliberative process they encourage

Evidence (cont)

- Important that evidence covers range of preventive and promotive interventions as well as curative ones
- Economic evaluation of system strengthening interventions is rare (e.g. pay-for-performance; strategic purchasing)
- Evidence on some social determinants and non-health interventions, although challenging, should not be ignored
- Considerable debate about appropriate thresholds for decision making; these must reflect opportunity costs and affordability (budget constraints/impact) in a particular setting; and not confuse the issue of thresholds with ensuring incentives for innovation.
- Thresholds have important implications for both health system sustainability and accountability.




Evidence (cont)

- Financial risk protection is also an objective of UHC: interventions may prevent households from falling into poverty, which can be captured through extended CEA or other methods
- Generating evidence is a dynamic process: need to keep the system up to date, be prepared to revise priorities as new evidence becomes available (examples from Thailand, New Zealand and South Korea)
- Horizon scanning / early assessments of new technologies are also part of the HITA continuum; important to remember “frugal innovation” as well as those innovations that improve outcomes but at considerable additional cost
- Particular challenges of de-listing / addressing the “trailing edge” of technologies



2. Using priority-setting evidence in making UHC decision



Understanding priority-setting

- Analysis of evidence is an essential starting point, but values and interests also come into play to protect human rights
 - Different interests can skew or better shape priority-setting
 - Different values can be in conflict

=> How to reconcile evidence, values and interests?
- Principle for priority setting: (1) should be impartial, (2) treating equal as equal, (3) should aim at fair distribution and health maximization and (4) should satisfy with condition of fair process
- Priority-setting has a dynamic nature
 - Values and interests change
 - Evidence changes: new interventions, new methods
- Monitoring and evaluation is an important part of the priority-setting process
 - Did the outcome of the priority-setting process play out as anticipated?



Participation in priority-setting processes

- Strive to create TRUST in the process
 - Process must be transparent
 - Process must be inclusive; engage with all stakeholders
 - Process must be impartial
- Will need to ACTIVELY ENABLE participation and facilitate dialogue across groups
 - Not all stakeholders are equal in power: gender issues, marginalized groups, language, information gaps
 - How do we level the playing field in which the priority-setting game is played?
 - Need mechanisms to strengthen individual capacity; strengthen institutional capacity; overcome gender barriers to participation, facilitate inclusion of marginalized groups
- Engage EARLY and OFTEN
- Need to ensure that participation is not only inclusive, but MEANINGFUL in that it allows the views of participants to be reflected in the ultimate decisions

Donors also influence priority-setting

- Donors also have priorities, which reflect evidence, values and interests, which may be in conflict with other stakeholders in the priority-setting process
- They also bring important resources to support
 - Generation of evidence
 - Development of HITA capacity
- Donors should play a supporting, not a dominant role
- Can a systematic, participatory and transparent process of priority-setting at the country level help to persuade donors to prioritize differently?

3. Priority setting in action: learning and sharing experiences


Real world experiences



The Universal Health Coverage Benefit Package of Thailand
โครงการศึกษาเพื่อพัฒนาชุดสิทธิประโยชน์ ภายใต้ระบบหลักประกันสุขภาพถ้วนหน้า

NLEM

National List of Essential Medicines



Country level experiences

- Generate evidence
 - Local training and team building
 - Tapping expertise from universities, research institutes, reverse brain drain (ROK)
 - National guideline developed, endorsed and applied
 - HITA units, agencies established with or without legal entity
 - Supply (evidence) induced demand (users)
- Use of evidence for coverage decision
 - Enabling factor is demand for evidence by purchaser organizations
 - Large population coverage by purchaser organization is critical
 - Potential platforms for coverage decision
 - National Essential Drug List committee: one of the main users of evidence
 - Benefit package committee: e.g. Philippines, Malawi, China, Thailand
 - Use of HITA to inform coverage decision is mandatory in a few countries.
- Institutionalizing and sustaining capacities is critical
 - Different trajectories: context specific
 - HITA agencies established without legislative endorsement (e.g. HITAP-Thailand)
 - HITA agencies established, then legislative endorsement (NECA Republic of Korea)
 - Legislative endorsement upfront, then HITA agency starts (UK NICE)




Regional networks

- Networks are important for strengthening capacity and supporting economic evaluation through regional collaborations.
- Regional HTA networks exist in Europe, America, Africa, Eastern Mediterranean, Asia Pacific and Latin America
 - Build on existing capacities
 - Promote knowledge sharing
 - Expanding research networks
- How do we ensure a financial base for such networks that protects their impartiality and independence?



Characteristics of HITA capacity development:

experiences of 7 high and middle income settings



Source: ppt file in PS2.5 Huntington D.

Challenges at country level

- **Countries with limited capacities**
 - Limited capacities: human and financial resources to generate evidence and use for coverage decisions
 - Existing global evidence may not fit well or applicable to LIC context
- **Countries having some capacities**
 - Seven case studies in Asia Pacific: Silo-based decision making, poor decision-making criteria, strict controls on research, undue influence of “expert opinion”
 - Inadequate process of priority setting: transparency, engagement by stakeholders
 - Know-do gaps: assessment—appraisal--coverage decisions
- Priority-implementation gaps: health systems capacities to deliver the prioritized benefit packages



Lessons learnt from country experiences

- Essential capacities
 - Generate evidence
 - Ensure due process of engaging stakeholders
 - Establish and implement appraisal criteria: cost-effectiveness, budget impact, equity, financial risk protection, social values, transparency
 - Develop and implement national HITA guideline including threshold, National Clinical Practice Guidelines
- No single pathway
 - Highly dependent on local context

Conclusion

- Priority setting is an essential enabling process for UHC
- Priority setting processes make the decisions about rationing explicit, and based on evidence, values and interests
- The process of assessment and appraisal is as important as the evidence
- To deliver these priorities we need strong health systems; but priority setting can contribute to this strengthening
- Achieving UHC will require the health system to deliver on priorities: requires capacity, system design and supporting interventions

Actions for driving priority setting for UHC

- Maximize use of global public goods: WHO-CHOICE, DCP, Cochrane library, NCD guidelines
- Build, strengthen, sustain institutional capacities in assessment, appraisal and decisionmaking
- Assure a fair process of priority setting: transparent, accountable, participative
- Promote networking, learning and sharing, contributing to global public goods
- Apply Bangkok Statement in line with national context

Lead Rapporteur

1. Prof Kara Hanson	3. Dr Jeff Johns
2. Dr Caryn Bredenkamp	4. Dr Viroj Tangcharoensathien

Rapporteur

1	Abha	Mehndiratta	25	Mari	Honda	49	Songhee	Cho
2	Ali	Subandoro	26	Marrten	Jansen	50	Songyot	Pilasant
3	Anit N.	Mukherjee	27	Masaaki	Uechi	51	Suchunya	Aungkulanon
4	Arimi	Mitsunaga	28	Minjoo	Kang	52	Suladda	Pongutta
5	Aviva	Tugendhaft	29	Nattadhanai	Rajatanavin	53	Sutayut	Osornprasop
6	Carol	Levin	30	Orana	Chandrasiri	54	Suteenoot	Tangsathitkulchai
7	Catherine	Pitt	31	Pandu	Harimurti	55	Suvimol	Niyomnaitham
8	Chalernpol	Chamchan	32	Pattarawalai	Talungchit	56	Tanita	Thaweethamcharoen
9	Chieko	Matsubara	33	Phumtham	Limwattananon	57	Thierry	Defechreux
10	Dewi	Indriani	34	Pien	Ploenbannakit	58	Thitiporn	Sukaew
11	Gloria Nenita V.	Velasco	35	Pitipa	Chongwatpol	59	Thunyarat	Anothaisintawee
12	Jeehyun	Hwang	36	Pochamana	Phisalprapa	60	Titiporn	Tuangratananon
13	Jintana	Jankhotkaew	37	Prapaporn	Noparatayaporn	61	Tommy	Wilkinson
14	Jomkwan	Yothasamut	38	Prasinee	Mahattanatawee	62	Udomsak	Saengow
15	Jun	Moriyama	39	Pritaporn	Kingkaew	63	Ully Adhie	Mulyani
16	Juntana	Pattanaphesaj	40	Rapeepong	Suphanchaimat	64	Vasinee	Singsa
17	Kanlaya	Teerawattananon	41	Robert	Liu	65	Vuong Lan	Mai
18	Kanokwaroon	Watananirun	42	Ryan	Li	66	Wanrudee	Isaranuwatchai
19	Karolyne	Carloss	43	Sandra	Khoury	67	Waraporn	Suwanwela
20	Kittiphong	Thiboonboon	44	Sangay	Wangmo	68	Xiaohui	Hou
21	Kobayashi	Seisi	45	Sarocho	Chootipongchatvat	69	Yothin	Thanormwat
22	Lester	Tan	46	Saudamini	Dabak	70	Yumiko	Miyashita
23	Manasigan	Kanchanachitra	47	Saya	Uchiyama	71	Yuna	Sakuma
24	Marc	Voelker	48	Sitaporn	Youngkong			

Rapporteur coordinator: Walaiporn Patcharanarumol, Inthira Yamabhai, Warisa Panichkriangkrai

Thank you for your attention